Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Fund of the Week: Fidelity Select Biotechnology (FBIOX)

Shauna O'Brien

|

Fidelity Investments logo
There have been a few industries that have been outperforming the S&P 500 since the beginning of 2015 – one of them being the biotechnology industry. While this run is nothing new, it is notable to mention that this industry is off to a good start for the year. This week, we have chosen the Fidelity® Select Biotechnology Fund (Liquid error: internal) as our fund of the week.

Inside the Fund

The fund was launched in 1985 and is managed by Rajiv Kaul. Currently, it has about $12 billion in assets under management (AUM). This fund is composed of healthcare companies of all sizes. The majority of these companies are based in the United States.

So far in 2015, the fund is up about 11%, which is in-line with the iShares NASDAQ Biotechnology Index (IBB) and well above the S&P 500 index, which is up about 3%.

Historical Performance

2010 2011 2012 2013 2014
11.41% 18.18% 36.59% 65.66% 35.05%
Largest Holdings

Nearly 30% of the fund’s portfolio is comprised of its top 5 holdings.

Symbol Stock Portfolio Weight YTD Performance
GILD Gilead Sciences 6.57% +12%
CELG Celgene 5.69% +10%
VRTX Vertex Pharmaceuticals 5.24% -2%
BIIB Biogen 5.13% +19%
ALXN Alexion Pharmaceuticals 4.44% -1%

The Bottom Line

The biotechnology industry is an industry that many aggressive investors have kept a close eye on over the years. Investors seeking exposure to the industry may consider a mutual fund like the Fidelity® Select Biotechnology (Liquid error: internal).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Read Next

Fidelity Investments logo

Fund of the Week: Fidelity Select Biotechnology (FBIOX)

Shauna O'Brien

|

There have been a few industries that have been outperforming the S&P 500 since the beginning of 2015 – one of them being the biotechnology industry. While this run is nothing new, it is notable to mention that this industry is off to a good start for the year. This week, we have chosen the Fidelity® Select Biotechnology Fund (Liquid error: internal) as our fund of the week.

Inside the Fund

The fund was launched in 1985 and is managed by Rajiv Kaul. Currently, it has about $12 billion in assets under management (AUM). This fund is composed of healthcare companies of all sizes. The majority of these companies are based in the United States.

So far in 2015, the fund is up about 11%, which is in-line with the iShares NASDAQ Biotechnology Index (IBB) and well above the S&P 500 index, which is up about 3%.

Historical Performance

2010 2011 2012 2013 2014
11.41% 18.18% 36.59% 65.66% 35.05%
Largest Holdings

Nearly 30% of the fund’s portfolio is comprised of its top 5 holdings.

Symbol Stock Portfolio Weight YTD Performance
GILD Gilead Sciences 6.57% +12%
CELG Celgene 5.69% +10%
VRTX Vertex Pharmaceuticals 5.24% -2%
BIIB Biogen 5.13% +19%
ALXN Alexion Pharmaceuticals 4.44% -1%

The Bottom Line

The biotechnology industry is an industry that many aggressive investors have kept a close eye on over the years. Investors seeking exposure to the industry may consider a mutual fund like the Fidelity® Select Biotechnology (Liquid error: internal).

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Read Next

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.